Irish general practitioner attitudes toward decriminalisation and medical use of cannabis: results from a national survey

Canna Clinical TrialsLeave a comment

Governmental debate in Ireland on the de facto decriminalisation of cannabis and legalisation for medical use is ongoing. A cannabis-based medicinal product (Sativex®) has recently been granted market authorisation in Ireland. Male GPs and those with higher levels of addiction training are more likely to support a more liberal drug policy approach to cannabis for personal use.

Pharmacology of cannabinoids in the treatment of epilepsy

Canna Clinical TrialsLeave a comment

The use of cannabis products in the treatment of epilepsy has long been of interest to researchers and clinicians alike; however, until recently very little published data were available to support its use. As cannabinoids and cannabis-based products are studied for efficacy as anticonvulsants, more investigation is needed regarding the specific targets of action, optimal drug delivery, and potential drug-drug interactions. This article is part of a Special Issue titled Cannabinoids and Epilepsy.

Maryland cannabis businesses cleared of conflict of interest, approved for launch

Cannabis news, Medical NewsLeave a comment

The Medical Cannabis Commission also issued dispensary licenses to two additional businesses, bringing the total number approved to sell medical marijuana to 6 Medical marijuana regulators in Maryland have approved licenses for two cannabis businesses that were under investigation for potential conflicts of interest, after concluding that no evidence had been uncovered that should preclude…

Structural barriers in access to medical marijuana in the USA-a systematic review protocol

Canna Clinical TrialsLeave a comment

There are 43 state medical marijuana programs in the USA, yet limited evidence is available on the demographic characteristics of the patient population accessing these programs. Moreover, insights into the social and structural barriers that inform patients’ success in accessing medical marijuana are limited. A current gap in the scientific literature exists regarding generalisable data on the social, cultural, and structural mechanisms that hinder access to medical marijuana among qualifying patients.